Company news

Equillium, Inc. news in 2022

Equillium, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

December 22, 2022

Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

December 15, 2022

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

December 5, 2022

Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates

November 13, 2022

Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022

November 13, 2022

Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata

November 9, 2022

Equillium to Present at Two Upcoming Investor Conferences

November 7, 2022

Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit

November 2, 2022

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

November 1, 2022

Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference

October 25, 2022

Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis

September 26, 2022

Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022

September 14, 2022

Equillium to Acquire Metacrine in All-Stock Transaction

September 5, 2022

Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates

August 14, 2022

Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit

July 27, 2022

Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates

May 11, 2022

Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association

May 11, 2022

Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists

May 8, 2022

Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR

April 24, 2022

Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology

April 3, 2022

Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates

March 22, 2022

Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation

March 22, 2022

Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

March 3, 2022

Equillium Announces Appointment of Barbara Troupin to Board of Directors

February 28, 2022

Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates

February 15, 2022

Equillium Provides Timing Update on Conference Presentations

February 14, 2022

Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference

February 8, 2022

Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR

January 9, 2022

Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

January 4, 2022

Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis

January 3, 2022

Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma

January 3, 2022

Decks in 2022